About Vigene Biosciences
Vigene Biosciences is a company based in Rockville (United States) founded in 2012 was acquired by Charles River Laboratories in May 2021. Vigene Biosciences has raised $10.5 million across 2 funding rounds from investors including Charles River Laboratories and Signet Healthcare Partners. The company has 45 employees as of December 31, 2018. Vigene Biosciences has completed 1 acquisition, including Omnia Biologics. Vigene Biosciences offers products and services including Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning. Vigene Biosciences operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Rockville, United States
- Employees 45 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vigene Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.5 M (USD)
in 2 rounds
-
Latest Funding Round
$3 M (USD), Series A
Mar 27, 2020
-
Investors
Charles River Laboratories
& 1 more
-
Employee Count
45
as on Dec 31, 2018
- Investments & Acquisitions
-
Acquired by
Charles River Laboratories
(May 17, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vigene Biosciences
Vigene Biosciences offers a comprehensive portfolio of products and services, including Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning.
Produces plasmid DNA for gene therapy applications to support research and development.
Develops viral vectors for delivering gene therapies in clinical and commercial settings.
Manufactures cell-based therapies for treating various diseases through advanced processes.
Packages viral vectors to ensure stability and efficacy for therapy applications.
Provides customized cloning services for biotechnology and therapeutic research needs.
People of Vigene Biosciences
Unlock access to complete
Funding Insights of Vigene Biosciences
Vigene Biosciences has successfully raised a total of $10.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vigene Biosciences
Vigene Biosciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Charles River Laboratories and Signet Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in North America and Europe
|
Locked | Locked | Locked | |
|
Provider of drug discovery and preclinical development services
|
Locked | Locked | Locked |
Investor details for Vigene Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vigene Biosciences
Vigene Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Omnia Biologics.
Investment portfolio details for Vigene Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Process development and manufacturing services for biologics are provided.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Vigene Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Vigene Biosciences
Detailed financials for Vigene Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vigene Biosciences Comparisons
Peer comparison for Vigene Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vigene Biosciences
Vigene Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Vigene Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vigene Biosciences
Complete news archive for Vigene Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vigene Biosciences
Vigene Biosciences was founded in 2012 and raised its 1st funding round 7 years after it was founded.
Vigene Biosciences is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Zairen Sun is the current CEO of Vigene Biosciences.
Vigene Biosciences is a funded company, having raised a total of $10.5M across 2 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Vigene Biosciences is 45.
Vigene Biosciences was founded in 2012 in Rockville, United States, and operates within the life sciences sector. Reagents for drug discovery and functional genomics are developed, with a portfolio that includes adeno-associated virus products, lentiviruses, human cDNA clones, mammalian expression vectors, and molecular bioreagents. Services provided encompass plasmid and adenoviral cloning, lentiviral cloning, AAV packaging, TALE nuclease design, and shRNA cloning, supporting research in biotechnology applications.
Vigene Biosciences's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Vigene Biosciences offers Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning.
Vigene Biosciences has made 1 acquisition, including Omnia Biologics.
Vigene Biosciences has 2 investors. Key investors include Charles River Laboratories, and Signet Healthcare Partners.